Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | 8th Annual Translational Science Event Only 7 Weeks Away!Cambridge Healthtech Institute's 8th Annual Translational Science Event Only 7 Weeks Away! Advance Registration Discount expires Friday, January 13th!
By: Camrbridge Healthtech Institute February 21-23, 2012 | San Francisco, CA | Part of the 19th International Molecular Med Tri-Conference - www.triconference.com Translational sciences can help increase not only the speed at which a drug reaches the clinic, but also the efficacy of the drug, the safety profile of that drug and the treatment population. Cambridge Healthtech Institute's Eighth Annual Translational Science conference at the 2012 Molecular Med Tri-Con will bring scientists from academia, industry and government together to discuss the role of translational science in drug discovery and development. While remaining in the forefront of pharmaceutical development news, translational science has become an integral component of modern drug discovery, starting with target validation and continuing through post-market surveillance. The role of the translational scientist may vary from organization to organization, but the underlying need to better understand and utilize the knowledge from both clinical and pre-clinical endeavors is crucial to reducing pharmaceutical attrition. What is the impact of having a pharmacodynamic vs. a prognostic biomarker? Can you implement a translational approach in a drug-diagnostic co-development project? What is the modern role for in vivo models in translational science? Learn from the experts and contribute to the conversation by bringing your experience to the forefront through interactive roundtables, moderated panel discussions and networking breaks. Case studies (from both small molecule and biologics) will be presented with an emphasis on the role of translational science in the success or failure of the compound. What are the lessons learned from the successes? Learn how these results are already translating back to pre-clinical research for similar targets. KEYNOTE PRESENTATIONS: Use of Biomarkers and Translational Science to Improve and Accelerate Oncology Drug Development J. Carl Barrett, Ph.D., Vice President, Translational Medicine, AstraZeneca Cancer Pharmacology in Translational Medicine Z. Alex Cao, Ph.D., Associate Director, Oncology Translational Research, Novartis Oncology Translational Medicine Presentations Include: Impact and Translational Opportunities of Pre-Clinical Imaging in Biomarker Discovery and Drug Development Paul McCracken, Ph.D., Director, Imaging, Eisai Research Institute Integrating Imaging in Early Drug Development: Glenn Liu, M.D., Associate Professor, Medicine, Carbone Cancer Center, Wisconsin Institute for Medical Research, University of Wisconsin Translational Imaging for De-risking Pharmaceutical Pipelines Yanping Luo, Ph.D., Group Leader, Translational Imaging, Global Pharmaceutical R&D, Abbott Laboratories SOMAmers Enable High Throughput Screening for Protein Biomarkers and Diagnostics Stephen A Williams, M.D., Ph.D., CMO, SomaLogic Use and Validation of Image Based Biomarkers of Drug Response: a CRO Perspective Patrick McConville, Ph.D., Chief Scientific Officer/COO, Molecular Imaging, Inc. PET Imaging as a Quantitative Biomarker in CNS Drug Development: Yiyun Henry Huang, Ph.D., Associate Professor, Co-Director, PET Center, Department of Diagnostic Radiology, Yale University The JAX Cancer Consortium: Changing the Course of Clinical Advancement Brandy Wilkinson, Ph.D., In Vivo Study Director, The Jackson Laboratory-West PANEL DISCUSSION: How Have Biomakers Been Applied in Clinical Development? Moderator: Prakash Purohit, Ph.D., Associate Director, Scientific Affairs, IPSEN Biomeasure, Inc. From Bench to Clinic: Quantitatively Assessing Cancer Targets and Biomarkers for Targeted Therapies Corinne Ramos, Ph.D., Executive Director of Clinical Research, Theranostics Health Biomarkers: How to Find them and Apply Them in Clinical Trials Suso Platero, Ph.D., Director, Oncology Biomarkers, Centocor, Ortho Biotech Oncology Research & Development, a unit of J&J PRD, LLC Back to Biomarker Basics for Drug Development Terry Walker, Ph.D., Director, Translational Immunology, Immunology & Autoimmunity Research Unit, Pfizer Molecular Profiling of Breast Cancer Trial Sets to Unravel Driving Oncogenic Hubs and Parallel Pathways Brian Leyland-Jones, M.D., Ph.D., Director, Winship Cancer Institute, Emory University Use of Experimental Medicine Models for Detecting Target Engagement in Clinical Trials of TRPV1 Antagonists Samer Eid, Ph.D.,Team Leader, Pain & Migraine Research, Neuroscience Drug Discovery, Merck Research Laboratories Biomarker Discovery and Validation: What is Missing Joerg Heyer, Ph.D., Director, Genetic Models, Translational Research, AVEO Pharmaceuticals Translational Research at Scripps Florida Patrick Griffin, Ph.D., Director, Translational Research, The Scripps Research Institute Translating Innovation into Personalized Medicine: A Centralized Approach for Fostering Research and Engaging Physicians in a Large National Community Hospital Network Jeffrey M. Otto, Ph.D., M.B.A., National Director, Catholic Health Initiative's Center for Translational Research Driving Innovation with Forward and Reverse Translation in the Academic Setting Bruce A. Sullenger, Ph.D., Director of the Duke Center for Translational Research, Joseph and Dorothy Beard Professor, Department of Surgery, Duke University Medical Center T-Cell Immunotherapy at UPenn: An Integrated Academic Translational Model for Success Michael Kalos, Ph.D., Director, Translational and Correlative Studies Laboratory, University of Pennsylvania School of Medicine Collaboration in Translational Science: Leveraging the Best of Both Worlds Moderator: Patricia McDonald, Ph.D., Associate Scientific Director, Translational Research, The Scripps Research Institute Informatics Tools for Translational Science: Bench to Bedside and Back James Cai, Ph.D., Head, Disease & Translational Informatics, Pharma Research & Early Development (pRED) Informatics, F. Hoffmann-La Roche, Inc. Building a Translational Informatics Infrastructure Organically Shoibal Datta, Ph.D., Associate Director, R&D Information Technology, Therapeutic Areas & Translational Medicine, Biogen Idec, Inc Implementation of Translational Research Informatics Platform at City of Hope Ajay Shah, Ph.D., Director, Research Informatics, City of Hope For more information visit http://www.triconference.com/ # # # Since 1992, Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|